drugset / Trial / NCT05235516

A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

NCT05235516

Phase 3 Active not recruiting 636 enrolled Akeso
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer

Timeline

Start
2022-06-21
Primary completion
2026-05
Completion
2029-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody Intravenous
Background Cisplatin Other / unclassified Intravenous

Indications